# Clinical trials recruiting in Argentina: 615 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 615 trials recruiting or not yet recruiting with a site in Argentina, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Argentina: 615 rows for $30.75, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 12 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/argentina

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 615
- Recruiting or not yet: 615
- Read on: November 19, 2026

## Trials

The 25 newest of 615, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 13, 2026 | NCT07935135 | Study of CMP-002 in Participants With SYNGAP1-Related Disorder | CAMP4 Therapeutics Corporation | Phase 1/2 | Not yet recruiting | Nervous System Disease | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935135) |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 23, 2026 | NCT07892378 | Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for... | Sponsor not shown (see the record) | Observational | Not yet recruiting | Prostate Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892378) |
| October 22, 2026 | NCT07890480 | Aztreonam-Avibactam in Immunocompromised Hosts | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Observational | Recruiting | Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Immunocompromised Host, Drug... | 814 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890480) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 15, 2026 | NCT07875595 | Immune Biomarkers for Predicting Complications After Liver Transplantation | Hospital Italiano de Buenos Aires | Observational | Recruiting | Liver Transplantation (LT), Immuno-suppression, Biomarkers / Blood, Rejection, Infections | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875595) |
| October 14, 2026 | NCT07873424 | Recumbent Cycling and Functional Electrical Stimulation for Lower Limb Rehabilitation | National Council of Scientific and Technical Research, Argentina | Not applicable | Recruiting | Muscle Fatigue, Functional Electrical Stimulation, Neuromuscular Rehabilitation | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873424) |
| October 7, 2026 | NCT07864415 | High-Flow Tracheal Oxygen During Spontaneous Breathing Trial | Argentinian Intensive Care Society | Not applicable | Recruiting | Mechanical Ventilation Weaning, Spontaneous Breathing Trial, High Flow Oxygen Therapy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864415) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 28, 2026 | NCT07845253 | Effect of Limosilactobacillus Reuteri on Social Deficits in Children With Autistic Spectrum Disorder | BioGaia AB | Not applicable | Not yet recruiting | Autism Spectrum Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845253) |
| September 25, 2026 | NCT07843225 | Standard Closure vs. Integrated Mesh-Fascial Closure (IMFC) for Incisional Hernia Repair | Hospital Zonal General De Agudos Mario V Larrain | Not applicable | Recruiting | Incisional Hernia Repair, Ventral Incisional Hernia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843225) |
| September 21, 2026 | NCT07830732 | A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A | Novo Nordisk A/S | Phase 3 | Recruiting | Haemophilia A | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830732) |
| September 9, 2026 | NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With... | Vividion Therapeutics, Inc. | Phase 2 | Recruiting | Colorectal Adenocarcinoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811193) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| September 1, 2026 | NCT07797335 | AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People... | Novo Nordisk A/S | Phase 3 | Recruiting | Type 2 Diabetes, Cardiovascular Risk | 1,778 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797335) |
| August 31, 2026 | NCT07794579 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1... | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal | 2,001 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794579) |
| August 28, 2026 | NCT07792031 | Comparing the Effect of Two Types of Pelvic Floor Muscle Stimulation Devices to Improve Symptoms of Urinary Incontinence in Women. | Espacio Gaspar Clinic | Not applicable | Recruiting | Urinary Incontinence, Mixed Urinary Incontinence, Urinary Incontinence (UI), Stress Urinary Incontinence (SUI), Stress... | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07792031) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Hospital Italiano de Buenos Aires | ABB | 92 |
| Instituto Alexander Fleming | Ciudad Autónoma de Buenos Aires | 45 |
| Hospital Universitario Austral | Pilar | 32 |
| Fundación Respirar | Buenos Aires | 30 |
| Hospital Aleman | Ciudad Autonoma de Buenos Aires | 24 |
| Fundacion Estudios Clinicos | Rosario | 21 |
| Hospital Britanico de Buenos Aires | Buenos Aires | 21 |
| INECO Neurociencias Oroño | Rosario | 19 |
| Centro Oncologico Korben | Buenos Aires | 19 |
| Hospital Provincial del Centenario | Rosario | 18 |
| Hospital Privado Universitario de Córdoba | Córdoba | 15 |
| Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada | Buenos Aires | 15 |
| Instituto de Investigaciones Clínicas Mar del Plata | Mar del Plata | 15 |
| Instituto Médico Río Cuarto | Río Cuarto | 14 |
| Instituto de Oncologia de Rosario | Rosario | 13 |
| Hospital Británico de Buenos Aires | Ciudad Autónoma de Buenos Aires | 12 |
| Instituto de Investigaciones Clinicas Mar del Plata | Mar del Plata | 12 |
| Centro de Investigaciones Clinicas del Litoral | Santa Fe | 12 |
| Fundación CORI para la Investigación y Prevención del Cáncer | La Rioja | 12 |
| Clinica Adventista Belgrano | Caba. | 12 |
| Instituto de Investigaciones Clínicas Córdoba | Córdoba | 11 |
| Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L | San Miguel de Tucumán | 11 |
| Centro de Investigaciones Medicas Tucuman | San Miguel de Tucumán | 10 |
| Instituto Medico Especializado Alexander Fleming | Buenos Aires | 10 |
| Cicemo Srl | Buenos Aires | 8 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 18 |
| Phase 2 | 88 |
| Phase 2/3 | 30 |
| Phase 3 | 330 |
| Phase 4 | 12 |
| Not applicable | 38 |
| Observational | 94 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 38 |
| Obesity | 23 |
| Breast Neoplasms | 20 |
| Diabetes Mellitus, Type 2 | 17 |
| Alzheimer Disease | 17 |
| Pulmonary Disease, Chronic Obstructive | 15 |
| Asthma | 14 |
| Heart Failure | 13 |
| Lung Neoplasms | 13 |
| Overweight | 12 |
| Cardiovascular Diseases | 11 |
| Neoplasms | 11 |
| Renal Insufficiency, Chronic | 11 |
| Colorectal Neoplasms | 11 |
| Lung Diseases | 10 |
| Hypertension | 9 |
| Lung Diseases, Interstitial | 9 |
| Multiple Myeloma | 9 |
| Lupus Erythematosus, Systemic | 9 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 8 |
| Ovarian Neoplasms | 8 |
| Colitis, Ulcerative | 8 |
| Prostatic Neoplasms | 8 |
| Neoplasm Metastasis | 8 |
| Dementia | 7 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 42 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 42 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 28 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 28 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 26 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 25 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 25 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 24 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 19 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 17 |
| Hospital Italiano de Buenos Aires | 14 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 13 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 12 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 8 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 7 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 7 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 5 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 5 |
| [Bayer](https://specstream.ai/data/clinical-trials/company/bayer) | 5 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 4 |
| [Alexion Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/alexion-pharmaceuticals-inc) | 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 3 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 3 |
| [Karuna Therapeutics, Inc., a Bristol Myers Squibb company](https://specstream.ai/data/clinical-trials/company/karuna-therapeutics-inc-a-bristol-myers-squibb-company) | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Carpenters in the United States](https://specstream.ai/data/businesses/carpenters/united-states)
- [Cafeterias in the United States](https://specstream.ai/data/businesses/cafeterias/united-states)
- [Business brokers in the United States](https://specstream.ai/data/businesses/business-brokers/united-states)
- [British restaurants in the United States](https://specstream.ai/data/businesses/british-restaurants/united-states)
- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
